Eli Lilly beats on earnings even as weight loss, diabetes drug sales fall short
Eli Lilly reported mixed results for the fourth quarter, even as demand for its blockbuster weight loss drug Zepbound and ...
Eli Lilly (NYSE:LLY) Speeds Up Weight Loss Drug Data Release
Weight loss drugs are huge these days, and Eli Lilly (LLY) is leading the pack when it comes to these. However, today’s ...
Lilly reassures investors that weight-loss drug demand is strong, shares rise
Eli Lilly forecast annual profit largely above Wall Street estimates on Thursday, banking on the launch of its popular ...
Eli Lilly to release late-stage data on next-generation weight loss drug retatrutide in 2025, earlier than expected
Eli Lilly expects to read out results from a study in people with obesity and osteoarthritis of the knee in 2025.
Eli Lilly reports mixed earnings, increases 2025 guidance
Eli Lilly reported fourth quarter and full year earnings for 2024 Thursday, with results largely beating Wall Street ...
Eli Lilly expects to beat profit forecasts on obesity drug demand
The world’s biggest drugmaker Eli Lilly has forecast that profits for the year will beat expectations, after two choppy quarters when disappointing sales of its blockbuster weight-loss drugs led to ...
Investor's Business Daily on MSN6h
Eli Lilly Jumps, Reversing Its Weight-Loss Setback, On A Strong 2025 Outlook
Eli Lilly stock reversed higher Thursday on its upbeat outlook despite lighter-than-expected fourth-quarter sales of its well-known weight-loss and diabetes drugs.Please watch the video at ...
thedailyupside2h
Weight-Loss Giants Have Investors Back on Their Sides
It can be hard to sate investors’ appetites, but if there’s two companies who should know how to do it, it’s these two.